Telescope Innovations Corp. develops enabling technologies and services for pharmaceutical, high-value chemical, and related laboratory markets. Company news commonly covers Self-Driving Laboratories, the DirectInject-LC™ automated sampling and analysis product, contract research services, customer installations, technology collaborations, and technical outreach to scientific and investor audiences.
Updates also address financial results, product fulfillment, hiring and operating expenses tied to growth, and Telescope's lithium processing portfolio, including DualPure™ and ReCRFT™ technologies for battery-material applications. The company's announcements connect automation, chemical process development, and materials R&D with recurring disclosures on revenue drivers, partnerships, and commercialization activity.
Telescope Innovations (TELIF) will attend the Planet MicroCap Toronto Investment Conference on October 27–29, 2026, to meet investors. The event takes place at the Arcadian Loft, 401 Bay Street. CEO Henry Dubina will present and answer questions on October 28 from 4:00–4:30 and hold one-on-one meetings on October 29. Management will discuss its Self-Driving Lab deployments, DirectInject-LC technology and growth strategy.
Telescope Innovations (TELIF) has been selected for Canada's business delegation to BIOPLUS-INTERPHEX Korea, taking place October 27–30, 2026, in Seoul. Founder and Chief Technology Officer Jason Hein and Vice President of Operations Paloma Prieto will represent the company.
The program includes industry visits, presentations on Physical AI and Self-Driving Laboratories in pharmaceutical research and development, and meetings with prospective partners, customers and investors. Telescope will also join an AI decision-making panel and BC-Gyeonggi Bio Connect 2026. Its existing Korean presence includes a Self-Driving Lab installed at the Korean Pharmaceutical and Biopharmaceutical Manufacturers Association in Seoul in December 2025.
Telescope Innovations (TELIF) will attend the Cantech Investment Conference in Toronto on October 8, 2026, as part of investor meetings.
Leadership will meet investors, analysts and industry participants on October 7 and 8 to discuss its automated laboratories, DirectInject-LC technology and growth strategy. Recent milestones include a June 2026 agreement for a crystallization-focused laboratory at a pharmaceutical company in Europe, a second laboratory installed at Pfizer in February 2026, and its first Asian deployment at KPBMA in Seoul in December 2025. Telescope and AGI SDA also launched a collaboration in March 2026 to develop a chemical reactor for automated laboratories. Dr. E. Neil Lewis joined the board in August 2026.
Telescope Innovations (TELIF) reported 60% gross revenue growth in preliminary, unaudited results for the fiscal year ended August 31, 2026. Revenue was approximately C$9.3 million, versus C$5.8 million in fiscal 2025, driven by laboratory platform deliveries, contract research services and DirectInject-LC sales.
Operating expenses rose to approximately C$13.9 million from C$7.3 million, including approximately C$2.0 million for investor awareness and marketing programs that concluded during the year. Net loss widened to approximately C$4.6 million from C$1.5 million; adjusted EBITDA loss widened to approximately C$2.7 million from C$0.4 million.
Telescope completed laboratory deployments in Korea, at Pfizer and for a pharmaceutical company's European operations, and raised approximately C$6.5 million in a private placement. All financial figures remain subject to audit and finalization.
Telescope Innovations (TELIF) announces that CTO Prof. Jason Hein has been invited to the National Science Foundation Programmable Cloud Laboratories (NSF PCL) Test Bed Kickoff Meeting in Washington, DC, held September 24–25, 2026.
The NSF PCL Test Bed is a US$380 million initiative funding 20 teams to build a national network of AI-enabled automated laboratories across seven scientific and engineering areas. The kickoff will set initial priorities for interoperable data standards, shared infrastructure, and coordinated safety and security. Prof. Hein plans to contribute Telescope’s commercial experience operating Self-Driving Laboratories, which the company presents as a basis for its participation.
Telescope Innovations (CSE: TELI, OTCQB: TELIF, FSE: J4U) appointed Dr. E. Neil Lewis to its Board of Directors, effective August 19, 2026. Dr. Lewis is a PhD chemist, NIH-tenured Senior Biophysical Researcher, FRSC/CChem, and founder or co-founder of three technology companies, including Spectral Dimensions.
In connection with the appointment, Telescope granted Dr. Lewis 100,000 stock options to purchase 100,000 common shares at an exercise price of $0.42 per share, exercisable for five years, subject to a Board-determined vesting schedule, under the company’s omnibus incentive plan and CSE policies. Telescope develops physical AI “Self-Driving Labs” and automation technologies for pharmaceutical and high-value chemical industries.
Telescope Innovations (OTCQB: TELIF) announced that Ali Pejman has resigned from its Board of Directors, effective July 14, 2026. According to Telescope, Pejman is expected to continue supporting the company as a consultant under an agreement to be finalized shortly, while the Board actively searches for a qualified replacement in line with Canadian securities laws and CSE policies.
Telescope Innovations (OTCQB: TELIF) will attend the Fastmarkets Global Lithium, Battery & Critical Materials conference in Las Vegas from June 23-25, 2026.
The company aims to advance commercial discussions for its Self-Driving Labs, automated sampling systems including DirectInject-LC™, and licensing of its high-purity lithium sulfide production process.
Telescope Innovations (OTCQB:TELIF) reported Q3 FY2026 results for the quarter ended May 31, 2026. Revenue was CAD 2.12 million with an adjusted EBITA loss of CAD 1.06 million. Expenses reached CAD 3.53 million.
Year-to-date gross revenue rose to CAD 6.5 million from CAD 3.6 million, an 80% increase. Operationally, Telescope secured a third Self-Driving Lab contract with a major global pharmaceutical company, advanced a collaboration with AGI Group on reactor technology, and invoiced an analysis platform based on its DirectInject-IC™ technology for lithium battery materials.
Telescope Innovations (OTCQB: TELIF) will present at Planet MicroCap Las Vegas 2026 on June 17, 2026, at 4:30 pm PST. Dr. Jeffrey Sherman will discuss DirectInject-LC reaction sampling, the AGI SDA reactor collaboration, and recent Self-Driving Lab deployments in Korea, Europe, and at Pfizer.